Intervention

AC

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting1

Common conditions9

Lead sponsors shown3

Clinical trials

3 shown

A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit SurvivorsNCT06411561 · 2024-12-26

RECRUITING

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerNCT03800836 · 2018-02-13

COMPLETED

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.NCT02789657 · 2016-11-21

COMPLETED

Common conditions

Breast Cancer2 Alzheimer's Disease1 Circadian Dysrhythmia1 Cognitive Decline1 Cognitive Impairment1 Critical Illness1 Delirium1 Dementia1 Sleep Disturbance1

Leading sponsors

Brown University 1 Hoffmann-La Roche 1 University of Washington 1

Trial status mix

COMPLETED2

RECRUITING1

Phase mix

NA1

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.